Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants.
BACKGROUND
Several studies showed the benefit of purging of acute myeloid leukemia (AML) stem cell transplants. We reported previously that purging by positive selection of CD34+ and CD133+ cells resulted in a 3-4 log tumor cell reduction (TCR) in CD34- and/or CD133- AML, but has been shown to be potentially applicable in only about 50% of cases. Similar to CD34 and CD133, CD90 marks the hematopoietic CD34 positive stem cells capable of full hematopoietic recovery after myeloablative chemotherapy, and therefore, in the present study, we explored whether a similar purging approach is possible using CD90.


METHODS
CD90 expression was established by flowcytometry in diagnosis AML on the clonogenic AML CD34+ blast population by flow cytometry. Positivity was defined as >3% CD90 (CD34+) expression on blasts. For the calculation of the efficacy of TCR by positive selection, AML blasts were recognized by either prelabeling diagnosis blasts with CD45-FITC in spiking model experiments or using expression of leukemia associated marker combinations both in spiking experiments and in real transplants.


RESULTS
In 119 patients with AML and myelodysplastic syndrome, we found coexpression of CD34 and CD90 (>3%) in 42 cases (35%). In AML patients 60 years or younger, representing the patients who are eligible for transplantation, only 23% (16/69) of the patients showed CD90 expression. Positive selection for CD90 in transplants containing CD90 negative AML resulted in a 2.8-4 log TCR in the models used.


CONCLUSIONS
Purging by positive selection using CD90 can potentially be applied effectively in the majority of AML patients 60 years or younger.
Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
Nicole
N
Feller
Angèle
A
Kelder
Guus
G
Westra
Gert J
GJ
Ossenkoppele
Gerrit J
GJ
Schuurhuis
D018952:Antigens, CD34 / Q000276:immunology / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000276:immunology; D016465:Bone Marrow Purging / Q000379:methods*; D005260:Female; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D018800:Thy-1 Antigens / Q000276:immunology*
D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D018800:Thy-1 Antigens